Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Efficacy and safety of steroid – free immunosuppression with tacrolimus and daclizumab in liver transplant recipients. Six years follow-up in a single centre

B Foroncewicz, K Mucha, E Ryszkowska, J Ziółkowski, M Krawczyk, L Pączek

Ann Transplant 2009; 14(1): 76-76 :: ID: 880479


Background: Corticosteroid-free maintenance immunosuppression eliminates the well-known corticosteroid-related side effects and may help to improve long-term outcome.
Material/Methods: We investigated whether a corticosteroid-free tacrolimus
(Tac) in combination with daclizumab (Dac) induction therapy, provides an
adequate immunosuppression after liver transplantation (OLTx). This 6-years,
single centre, retrospective study involved 25 liver transplant recipients randomized to a Tac/Dac regimen (n=7) or a Tac/corticosteroids (Tac/CS)
regimen (n=18), according to the protocol of the MASTER study. Patient's and graft's survival, incidence of acute rejection and diabetes mellitus, liver and kidney function as well as BMI were compared between the groups. In order to quantify the therapy-related adverse events the total length of hospitalization was analysed.
Results: Demographic data including age, gender and ischemic time were similar in both groups. No signifi cant difference was found in patient and graft
survival in both treatment arms (71.5% in Tac/Dac and 94.5% in Tac/CS, p=NS). The incidence of biopsy-proven acute rejection was 16% in Tac/CS and 14% in Tac/Dac group (P=NS). Renal and liver function was also similar in both groups. However, compared with the Tac/CS regimen, a significantly reduced incidence of new-onset diabetes mellitus (DM) (14% vs. 22%, p<0.05) was found with steroid-free immunosuppression. Also the blood pressure (BP) and BMI were significantly lower in Tac/Dac patients (p<0.05). Total time of hospitalization did not differ significantly between the groups (46.1 days/person in Tac/CS vs. 55.1 in Tac/Dac, p=NS)
Conclusions: Corticosteroid-free immunosuppression with a Tac/Dac regimen
is as effective at yielding good patient and graft survival as a standard double
regimen of Tac/CS. The lower incidence of DM and better BP and BMI control in Tac/Dac group may indicate higher safety of Tac/Dac treatment.

Keywords: Immunosuppression, Liver Transplantation, clinical outcome

Add Comment 0 Comments

In Press

Original article  

Engraftment Syndrome in Autologous Hematopoietic Stem Cell Transplant Patients: Incidence, Associated Risk ...

Ann Transplant In Press; DOI: 10.12659/AOT.944043  

Original article  

Comparative Study of Acute Kidney Injury in Liver Transplantation: Donation after Circulatory Death versus ...

Ann Transplant In Press; DOI: 10.12659/AOT.944077  

Original article  

Abnormal Liver Biopsies of Donor Grafts in Pediatric Liver Transplantation: How Do They Fare?

Ann Transplant In Press; DOI: 10.12659/AOT.944245  

Original article  

Kidney After Lung Transplants or Combined Kidney–Lung Transplantation: A Single-Center Retrospective Cohort...

Ann Transplant In Press; DOI: 10.12659/AOT.944049  

Most Viewed Current Articles

05 Apr 2022 : Original article   12,404

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   9,258

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

12 Jan 2022 : Original article   8,843

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

15 Mar 2022 : Case report   6,648

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358